8-K/A: CalciMedica Secures Up to $55 Million in Private Placement to Advance Clinical Programs

CalciMedica has announced a private placement to raise up to $55 million, including $20.4 million upfront, to fund clinical trials for its drug candidate Auxora.

Summary

• CalciMedica has entered into a securities purchase agreement to raise up to approximately $55 million in gross proceeds through a private placement.
• The financing includes an initial upfront funding of $20.4 million and up to an additional approximately $34.2 million upon exercise of accompanying warrants.
• The private placement involves the issuance of 5,113,812 shares of common stock (and pre-funded warrants for 351,352 shares) and warrants to purchase up to 5,465,164 shares of common stock.
• The combined purchase price is $3.70 per share and accompanying warrants, or $4.3915 per share and accompanying warrants for directors, employees or consultants.
• Tranche A warrants, exercisable at $5.36 per share, are for up to 2,732,582 shares and expire 30 days after topline data from the CARPO trial or December 31, 2024.
• Tranche B warrants, exercisable at $7.15 per share, are for up to 2,732,582 shares and expire 30 days after topline data from the planned Phase 2 AKI trial or December 31, 2026.
• The company intends to use the upfront net proceeds to fund ongoing and planned Phase 2 clinical trials for Auxora in acute pancreatitis (AP) and acute kidney injury (AKI).
• The aggregate net proceeds, assuming full warrant exercise, are expected to fund subsequent, potentially pivotal clinical trials and other work in the AP and AKI programs.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a significant capital raise and the advancement of clinical programs. However, the reliance on warrant exercises for additional funding and the potential for dilution temper the overall sentiment.

Positives

• The private placement provides significant funding to advance CalciMedica's clinical programs.
• The participation of new healthcare-dedicated investors indicates confidence in the company's potential.
• The funding will enable the initiation of a Phase 2 clinical trial in AKI, a condition with significant unmet medical need.
• The aggregate net proceeds are expected to be sufficient to fund the company through subsequent, potentially pivotal clinical trials.

Negatives

• The private placement involves the issuance of a significant number of new shares, which could dilute existing shareholders.
• The additional $34.2 million in funding is contingent on the exercise of warrants, which may not occur.
• The warrants have relatively short expiration dates, which could put pressure on the company to achieve positive clinical results.

Risks

• The company's ability to execute its plans and strategies is subject to risks and uncertainties.
• Obtaining and maintaining regulatory approval for Auxora is not guaranteed.
• Results from clinical trials may not be indicative of results that may be observed in the future.
• There are potential safety and other complications from Auxora.
• The company's ability to protect its intellectual property position is subject to risks.
• Economic, business, competitive, and/or regulatory factors could affect the company's business.

Future Outlook

The company expects the aggregate net proceeds from the private placement, assuming full warrant exercise, to be sufficient to fund subsequent, potentially pivotal clinical trials and other work in its AP and AKI programs. The company also plans to initiate a Phase 2 study in acute kidney injury (AKI) in 1H 2024.

Management Comments

• We are excited about this vote of confidence from leading life science investors, which validates the progress we are making in the clinic with Auxora targeting acute inflammatory and immunologic diseases, said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica.
• This financing allows us to initiate clinical trials in AKI, a condition with significant unmet medical need, and brings us closer to our goal of making a meaningful difference in the lives of critically ill patients.

Industry Context

This announcement comes as the biopharmaceutical industry continues to seek funding for clinical trials and drug development. CalciMedica's focus on CRAC channel inhibition therapies for inflammatory and immunologic diseases aligns with the growing interest in novel treatments for these conditions.

Comparison to Industry Standards

• The private placement structure, with upfront funding and additional proceeds contingent on warrant exercises, is a common approach in the biotech industry.
• The participation of healthcare-dedicated investors like Deerfield Management, Soleus Capital, Stonepine Capital Management and Aisling Capital is a positive sign, as these firms typically conduct thorough due diligence before investing.
• The use of proceeds to fund Phase 2 clinical trials is consistent with the typical development pathway for biopharmaceutical companies.
• The warrant exercise prices of $5.36 and $7.15 per share are relatively high, suggesting that investors expect significant upside potential in CalciMedica's stock price.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the company's increased financial stability and growth prospects.
• Patients may benefit from the development of new therapies for AP and AKI.
• Investors may see potential returns if the company's clinical programs are successful.

Next Steps

• The company will initiate a Phase 2 clinical trial in AKI in 1H 2024.
• The company will continue its Phase 2b CARPO trial of Auxora in AP patients with SIRS, with topline data expected in the first half of 2024.
• The company will continue the Phase 1/2 CRSPA AIPT study, with additional data expected by 2H 2024.
• The company will file a registration statement with the SEC registering the resale of the shares of common stock purchased in the private placement and shares of common stock underlying the warrants.

Key Dates

Keywords

private placement, clinical trials, Auxora, acute pancreatitis, acute kidney injury, warrants, biopharmaceutical, CRAC channel inhibition, Deerfield Management, Soleus Capital, Stonepine Capital Management, Aisling Capital, Sanderling Ventures, Bering Capital